Yarbrough Capital LLC Makes New $277,000 Investment in Cardiff Oncology, Inc. (NASDAQ:CRDF)

Yarbrough Capital LLC bought a new position in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 88,163 shares of the company's stock, valued at approximately $277,000. Yarbrough Capital LLC owned about 0.13% of Cardiff Oncology as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in CRDF. BNP Paribas Financial Markets purchased a new position in Cardiff Oncology in the 4th quarter worth approximately $25,000. Thoroughbred Financial Services LLC increased its holdings in shares of Cardiff Oncology by 43.8% in the 4th quarter. Thoroughbred Financial Services LLC now owns 19,614 shares of the company's stock worth $85,000 after purchasing an additional 5,970 shares in the last quarter. American Century Companies Inc. raised its stake in shares of Cardiff Oncology by 12.8% in the fourth quarter. American Century Companies Inc. now owns 53,955 shares of the company's stock worth $234,000 after purchasing an additional 6,140 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Cardiff Oncology by 38.1% during the fourth quarter. Wells Fargo & Company MN now owns 32,064 shares of the company's stock valued at $139,000 after purchasing an additional 8,851 shares in the last quarter. Finally, Barclays PLC lifted its holdings in shares of Cardiff Oncology by 17.9% during the fourth quarter. Barclays PLC now owns 62,596 shares of the company's stock valued at $272,000 after purchasing an additional 9,507 shares in the last quarter. Institutional investors own 16.29% of the company's stock.

Cardiff Oncology Trading Down 0.5%

Shares of CRDF stock traded down $0.02 on Monday, reaching $3.86. The company's stock had a trading volume of 959,297 shares, compared to its average volume of 1,155,892. The stock's fifty day simple moving average is $2.90 and its 200-day simple moving average is $3.48. Cardiff Oncology, Inc. has a 1 year low of $2.01 and a 1 year high of $5.64. The company has a market capitalization of $256.79 million, a price-to-earnings ratio of -4.11 and a beta of 1.61.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The business had revenue of $0.11 million during the quarter, compared to analysts' expectations of $0.09 million. Cardiff Oncology had a negative return on equity of 73.97% and a negative net margin of 6,238.17%. Equities research analysts forecast that Cardiff Oncology, Inc. will post -0.99 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright raised their target price on shares of Cardiff Oncology from $17.00 to $18.00 and gave the stock a "buy" rating in a report on Friday, May 9th.

Cardiff Oncology Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.